Recent positive Phase 3 data for the companies’ partnered mRNA cancer vaccine intismeran autogene, which drove sharp share-price gains in August 2026, has reinforced their decade-long collaboration without prompting consolidation talks. Merck continues to pursue bolt-on acquisitions in life sciences and oncology, such as its Bio-Techne and Terns deals, while Moderna focuses on pipeline prioritization, licensing select assets, and manufacturing scale-up for individualized therapies. Market-implied odds near 99% against a 2026 announcement reflect this stable partnership structure, differing strategic priorities, and absence of regulatory or activist pressure for a merger. Tail risks remain limited to an unforeseen macroeconomic shock or sudden board-level strategic pivot, both viewed as remote given current capital allocation and competitive positioning.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日はい
1% 確率
新規
新規
2026/12/31
はい
1% 確率
新規
新規
2026/12/31
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 data for the companies’ partnered mRNA cancer vaccine intismeran autogene, which drove sharp share-price gains in August 2026, has reinforced their decade-long collaboration without prompting consolidation talks. Merck continues to pursue bolt-on acquisitions in life sciences and oncology, such as its Bio-Techne and Terns deals, while Moderna focuses on pipeline prioritization, licensing select assets, and manufacturing scale-up for individualized therapies. Market-implied odds near 99% against a 2026 announcement reflect this stable partnership structure, differing strategic priorities, and absence of regulatory or activist pressure for a merger. Tail risks remain limited to an unforeseen macroeconomic shock or sudden board-level strategic pivot, both viewed as remote given current capital allocation and competitive positioning.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
マーケット開始日： Aug 19, 2026, 3:58 PM ET
音量
$425終了日
2027/01/01マーケット開始日
Aug 19, 2026, 3:58 PM ETリゾルバー
0x65070BE91...This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.Recent positive Phase 3 data for the companies’ partnered mRNA cancer vaccine intismeran autogene, which drove sharp share-price gains in August 2026, has reinforced their decade-long collaboration without prompting consolidation talks. Merck continues to pursue bolt-on acquisitions in life sciences and oncology, such as its Bio-Techne and Terns deals, while Moderna focuses on pipeline prioritization, licensing select assets, and manufacturing scale-up for individualized therapies. Market-implied odds near 99% against a 2026 announcement reflect this stable partnership structure, differing strategic priorities, and absence of regulatory or activist pressure for a merger. Tail risks remain limited to an unforeseen macroeconomic shock or sudden board-level strategic pivot, both viewed as remote given current capital allocation and competitive positioning.
This market will resolve to "Yes" if it is officially announced that Merck & Co. (MRK) will be, has been, or is being acquired by or merged with Moderna (MRNA), or vice versa, by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
A qualifying merger or acquisition must encompass both MRK and MRNA or their subsidiaries.
An announcement by MRK or MRNA within this market's timeframe will qualify for a "Yes" resolution, regardless of whether or when the announced acquisition/merger actually occurs.
A bid or offer announcement without the indication of a settled agreement will not qualify.
Announcements of partial sales may count, as long as the acquiring company announces the acquisition of a controlling interest in the other company. A "controlling interest" refers to a change in ownership sufficient to control the company's strategic decisions (typically more than 50% of equity, or equivalent control via voting and governance rights). Transactions or investments that do not result in a transfer of controlling interest will not count.
The primary resolution source for this market will be official information from MRK and MRNA; however, a consensus of credible reporting may also be used.
音量
$425終了日
2027/01/01マーケット開始日
Aug 19, 2026, 3:58 PM ETリゾルバー
0x65070BE91...Recent positive Phase 3 data for the companies’ partnered mRNA cancer vaccine intismeran autogene, which drove sharp share-price gains in August 2026, has reinforced their decade-long collaboration without prompting consolidation talks. Merck continues to pursue bolt-on acquisitions in life sciences and oncology, such as its Bio-Techne and Terns deals, while Moderna focuses on pipeline prioritization, licensing select assets, and manufacturing scale-up for individualized therapies. Market-implied odds near 99% against a 2026 announcement reflect this stable partnership structure, differing strategic priorities, and absence of regulatory or activist pressure for a merger. Tail risks remain limited to an unforeseen macroeconomic shock or sudden board-level strategic pivot, both viewed as remote given current capital allocation and competitive positioning.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問